20 completed, 2 recruiting, 2 terminated, 2 unknown. 17 Phase 3, 7 Phase 2, 3 Phase 1, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 13, Terminated 2, Recruiting 1, Unknown 1 |
| Phase 2 | 7 | Completed 5, Recruiting 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Phase 4 | 3 | Completed 3 |
Follow Bacterial Conjunctivitis: new trials by email Literature Review of Bacterial Conjunctivitis trials Research Report on Bacterial Conjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis SUM-191, Placebo - Bacterial Conjunctivitis | Phase 1 / Phase 2 | Recruiting | Senju USA, Inc. | 426 | 2026-06-25 | 2026-06-30 |
| Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis Fusidic Acid 1%, Placebo - Bacterial Conjunctivitis | Phase 3 | Recruiting | Baxis Pharmaceuticals, Inc. | 400 | 2025-03-21 | 2026-03-17 |
| Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects PRO-231, VIGAMOXI® - Ophthalmological Agent Toxicity, Bacterial Conjunctivitis | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 37 | 2024-01-30 | 2025-06-15 |
| Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers azithromycin eye drops by essex, azithromycin eye drops - Bacterial Conjunctivitis | Phase 1 | Unknown | Beijing Tongren Hospital | 56 | 2017-07-07 | 2017-08-01 |
| Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo SHP640, PVP-I 0.6%, Placebo - Bacterial Conjunctivitis | Phase 3 | Completed | Shire | 753 | 2017-03-29 | 2021-06-09 |
| Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis Vancomycin 1.1%, Placebo - Bacterial Conjunctivitis | Phase 3 | Completed | Kurobe LLC | 303 | 2015-05-01 | 2024-10-23 |
| Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) PRO-157, Vigamox, Zymar® - Bacterial Conjunctivitis | Phase 2 | Completed | Laboratorios Sophia S.A de C.V. | 150 | 2015-03-01 | 2019-05-22 |
| Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis Auriclosene Solution 0.3%, Auriclosene Vehicle - Bacterial Conjunctivitis | Phase 2 | Completed | NovaBay Pharmaceuticals, Inc. | 217 | 2013-06-01 | 2015-05-28 |
| Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis Besifloxacin, Vehicle - Bacterial Conjunctivitis | Phase 3 | Terminated | Bausch & Lomb Incorporated | 136 | 2013-02-01 | 2014-10-01 |
| An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients Moxifloxacin ophthalmic solution, 0.5%, Ofloxacin ophthalmic solution, 0.3% - Bacterial Conjunctivitis | Phase 3 | Completed | Alcon Research | 985 | 2012-05-01 | 2015-05-12 |
| Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis Besivance, Gatifloxacin - Bacterial Conjunctivitis | Phase 3 | Terminated | Bausch & Lomb Incorporated | 33 | 2011-05-01 | 2014-09-03 |
| Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis MAXINOM®, Maxitrol® - Bacterial Conjunctivitis, Acute | Phase 3 | Unknown | Azidus Brasil | 70 | 2011-02-01 | 2010-10-25 |
| Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension, AL-15469A 0.5%, AL-6515 0.3% - Bacterial Conjunctivitis | Phase 2 | Withdrawn | Alcon Research | 2011-01-01 | 2011-12-01 | |
| Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Besivance, Vehicle - Bacterial Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 518 | 2010-06-01 | 2013-05-01 |
| Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis Besifloxacin, Vehicle (Placebo) - Bacterial Conjunctivitis | Phase 2 / Phase 3 | Completed | Bausch & Lomb Incorporated | 474 | 2009-10-01 | 2012-03-29 |
| Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%, Moxifloxacin AF Vehicle - Bacterial Conjunctivitis | Phase 3 | Completed | Alcon Research | 1179 | 2008-10-01 | 2018-01-02 |
| Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Vigamox Ophthalmic Solution, BSS placebo - Bacterial Conjunctivitis | Phase 4 | Completed | Alcon Research | 24 | 2008-10-01 | 2010-03-31 |
| A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Gatifloxacin 0.5% eye drops, placebo eye drops - Bacterial Conjunctivitis | Phase 3 | Completed | Allergan | 859 | 2008-02-01 | 2019-04-23 |
| A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Gatifloxacin 0.5% eye drops, placebo eye drops - Bacterial Conjunctivitis | Phase 3 | Completed | Allergan | 578 | 2007-08-01 | 2011-11-30 |
| A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis gatifloxacin, moxifloxacin 0.5% eye drops - Bacterial Conjunctivitis | Phase 4 | Completed | Allergan | 171 | 2007-06-01 | 2011-09-21 |
Showing 20 of 27. Sign in to see all of them.
Conjunctivitis, Bacterial (27) · Conjunctivitis (5) · Eye Infections (3) · Eye Infections, Bacterial (2) · Bacterial Infections (1) · Conjunctival Diseases (1) · Eye Diseases (1) · Infections (1)
Bacterial Infections and Mycoses (27) · Bacterial Infections (26) · Conjunctival Diseases (26) · Eye Diseases (26) · Infections (26) · Eye Infections, Bacterial (25) · Eye Infections (24) · Conjunctivitis (22)
Moxifloxacin (6) · Gatifloxacin (5) · besifloxacin (5) · Ophthalmic Solutions (4) · Azithromycin (3) · Alkalies (1) · Maxitrol (1) · NVC-422 (1) · Quinolones (1) · Tobramycin (1) · pazufloxacin (1)
Alcon Research (7) · Bausch & Lomb Incorporated (5) · Allergan (3) · Laboratorios Sophia S.A de C.V. (2) · Merck Sharp & Dohme LLC (2) · Azidus Brasil (1) · Baxis Pharmaceuticals, Inc. (1) · Beijing Tongren Hospital (1) · Kurobe LLC (1) · Laser Microsurgery Centre, Poland (1) · NovaBay Pharmaceuticals, Inc. (1) · Senju USA, Inc. (1) · Shire (1)
United States (18) · Canada (2) · China (2) · Mexico (2) · Poland (2) · Australia (1) · Austria (1) · Brazil (1) · Estonia (1) · France (1) · Hungary (1) · India (1) · Israel (1) · Italy (1) · Puerto Rico (1)
Johnson Varughese (2) · Alejandra Sanchez-Rios, MD (1) · Catherine Allaire, MD (1) · David W. Stroman, Ph.D. (1) · Helen Yu, Lead CSM (1) · Jerzy Szaflik, MD,Ph.D. (1) · Leopoldo Baiza, MD (1) · Michael R Paterno, OD (1) · Stella Robertson, Ph.D. (1) · Steven J. Lichtenstein, M.D. (1) · Timothy Comstock, OD (1) · Xiuli Zhao (1)
PMID 21681652, PMID 17652708, PMID 18374301, PMID 19393842, PMID 20629472, PMID 21397770, PMID 22420526, PMID 22644963, PMID 25244402, PMID 29602567, PMID 32841261
2016 (1)